Tandem Diabetes Care [TNDM] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Tandem Diabetes Care
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Tandem Diabetes Care wins in 5 metrics, Abbott Laboratories wins in 13 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Tandem Diabetes Care | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -10.01 | 16.89 | Tandem Diabetes Care |
| Price-to-Book Ratio | 7.45 | 4.63 | Abbott Laboratories |
| Debt-to-Equity Ratio | 340.56 | 26.50 | Abbott Laboratories |
| PEG Ratio | -0.15 | 0.46 | Tandem Diabetes Care |
| EV/EBITDA | -14.92 | 21.02 | Tandem Diabetes Care |
| Profit Margin (TTM) | -20.51% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -13.24% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | -111.92% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | -6.41% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $4.99M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -59.51% | 15.17% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 0.99 | 5.43 | Tandem Diabetes Care |
| Enterprise Value | $1.13B | $240.70B | Abbott Laboratories |
| EV/Revenue Ratio | 1.13 | 5.58 | Tandem Diabetes Care |
| Gross Profit Margin (TTM) | 52.29% | 56.44% | Abbott Laboratories |
| Revenue per Share (TTM) | $15 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-3.08 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.49 | 0.70 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Tandem Diabetes Care vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Tandem Diabetes Care | 2.04% | 27.31% | 20.08% | -7.63% | -10.92% | -58.12% |
| Abbott Laboratories | -0.63% | 0.47% | 1.16% | 0.03% | 7.11% | 17.89% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Tandem Diabetes Care | -59.51% | -70.67% | -87.36% | -81.74% | -93.13% | -93.13% |
| Abbott Laboratories | 15.17% | 32.53% | 21.95% | 216.77% | 424.26% | 553.67% |
News Based Sentiment: Tandem Diabetes Care vs Abbott Laboratories
Tandem Diabetes Care
News based Sentiment: MIXED
October presented a complex picture for Tandem, with a serious product malfunction investigation unfolding alongside positive regulatory clearances, encouraging insider buying, and solid Q2 revenue growth. These competing factors create significant uncertainty and make it a pivotal month for the company's future trajectory.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories delivered strong Q2 earnings and raised guidance, leading to positive analyst revisions and continued institutional investment. While some valuation models suggest the stock may be overvalued, the overall narrative is positive, driven by strong financial performance and a promising product pipeline.
Performance & Financial Health Analysis: Tandem Diabetes Care vs Abbott Laboratories
| Metric | TNDM | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.01B | $234.39B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 1,690,569 | 5,683,430 |
| 90 Day Avg. Volume | 1,849,033 | 5,498,563 |
| Last Close | $15.01 | $133.74 |
| 52 Week Range | $9.98 - $42.70 | $110.86 - $141.23 |
| % from 52W High | -64.85% | -5.30% |
| All-Time High | $302.50 (Jan 13, 2014) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -95.04% | -6.21% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.07% |
| Quarterly Earnings Growth | N/A | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.21% | 0.32% |
| Operating Margin (TTM) | -0.13% | 0.20% |
| Return on Equity (TTM) | -1.12% | 0.31% |
| Debt to Equity (MRQ) | 340.56 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.97 | $29.05 |
| Cash per Share (MRQ) | $4.67 | $4.18 |
| Operating Cash Flow (TTM) | $9.72M | $9.04B |
| Levered Free Cash Flow (TTM) | $31.96M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Tandem Diabetes Care vs Abbott Laboratories
| Metric | TNDM | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -10.01 | 16.89 |
| Forward P/E | -12.16 | 26.08 |
| PEG Ratio | -0.15 | 0.46 |
| Price to Sales (TTM) | 0.99 | 5.43 |
| Price to Book (MRQ) | 7.45 | 4.63 |
| Market Capitalization | ||
| Market Capitalization | $1.01B | $234.39B |
| Enterprise Value | $1.13B | $240.70B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.13 | 5.58 |
| Enterprise to EBITDA | -14.92 | 21.02 |
| Risk & Other Metrics | ||
| Beta | 1.49 | 0.70 |
| Book Value per Share (MRQ) | $1.97 | $29.05 |
Financial Statements Comparison: Tandem Diabetes Care vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TNDM | ABT |
|---|---|---|
| Revenue/Sales | $234.42M | $10.36B |
| Cost of Goods Sold | $116.02M | $4.47B |
| Gross Profit | $118.41M | $5.89B |
| Research & Development | $125.43M | $716.00M |
| Operating Income (EBIT) | $-120.88M | $1.69B |
| EBITDA | $-116.42M | $2.66B |
| Pre-Tax Income | $-122.09M | $1.78B |
| Income Tax | $8.47M | $453.00M |
| Net Income (Profit) | $-130.56M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TNDM | ABT |
|---|---|---|
| Cash & Equivalents | $53.57M | $6.53B |
| Total Current Assets | $663.44M | $23.15B |
| Total Current Liabilities | $288.18M | $13.00B |
| Long-Term Debt | $431.75M | $12.74B |
| Total Shareholders Equity | $155.29M | $49.06B |
| Retained Earnings | $-1.18B | $47.72B |
| Property, Plant & Equipment | $79.22M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TNDM | ABT |
|---|---|---|
| Operating Cash Flow | $-6.71M | $1.42B |
| Capital Expenditures | $-6.21M | $-484.00M |
| Free Cash Flow | $-15.70M | $933.00M |
| Debt Repayment | $-40.76M | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | TNDM | ABT |
|---|---|---|
| Shares Short | 7.93M | 18.07M |
| Short Ratio | 4.28 | 3.68 |
| Short % of Float | 0.16% | 0.01% |
| Average Daily Volume (10 Day) | 1,690,569 | 5,683,430 |
| Average Daily Volume (90 Day) | 1,849,033 | 5,498,563 |
| Shares Outstanding | 66.26M | 1.73B |
| Float Shares | 61.82M | 1.73B |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.20% | 0.81% |
Dividend Analysis & Yield Comparison: Tandem Diabetes Care vs Abbott Laboratories
| Metric | TNDM | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |